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Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in
SIADH rats. The present study was undertaken to determine whether the
non-peptide V2 antidiuretic hormone (ADH) antagonist 5-dimethylamino-
1{4-(2-methylbenzoylamino)benzoyl}-2,3,4,5-tetrahydro-1H-benzazepine(OPC-3 1260) normalized hyponatremia in rats with an experimental
syndrome of inappropriate secretion of ADH (SIADH). Rats were
administered V2 agonist 1-deamino-8-D-arginine vasopressin (dDAVP)
subcutaneously at a rate of 5 ng/hr using an osmotic minipump and a 40
mi/day liquid diet. Serum sodium levels (SNa) and serum osmolality
(Sosm) markedly decreased to 119 mEq/liter and 249 mOsmlkg H20,
respectively, 48 hours after the start of dDAVP administration. Hy-
ponatremia persisted in a similar magnitude during the observation
period of 14 days. On days 7 to 13 OPC-3l260, administered 5mg/kg per
day orally, promptly raised SNa and Sosm to 134 mEq/liter and 282
mOsm/kg H20 in half a day, respectively, followed by the normaliza-
tion of SNa and Sosm during the rest of the observation period. The
cease of administration of OPC-3 1260 again decreased SNa and Sosm in
rats receiving dDAVP. In contrast, SNa and Ssm were within the
normal values in rats receiving 0.15 M NaCI, a vehicle for dDAVP, in
the presence or absence of OPC-3 1260. The administration of OPC-
31260 promptly caused marked water diuresis on day 7 in the hypona-
tremic rats receiving dDAVP, namely 5 mg/kg OPC-31260 markedly
increased urinary volume and decreased Uosm. These results indicate
that there is dilutional hyponatremia in rats receiving dDAVP and 40
mi/day liquid diets, and that OPC-3 1260 is an effective therapeutic for
hyponatremia associated with dDA VP-induced SIADH.
Clinical and laboratory experiments have demonstrated that
the syndrome of inappropriate secretion of antidiuretic hor-
mone (SIADH) is associated with marked hyponatremia [1—6].
Persistent elevation of plasma levels of radioimmunoassayable
antidiuretic hormone (ADH) was shown in spite of hypoosmo-
lality, Which should suppress the osmotic release of ADH to
undetectable levels [7]. Reversal of hyponatremia by using a
specific inhibitor of ADH would provide quantitative and
conclusive evidence for a role of ADH in SIADH. This is
important since other factors may also contribute to hyponatre-
mia. Such studies had been examined by using peptide ADH
antagonists synthesized by Manning and Sawyer [8, 9]. These
antagonists antagonize to the antidiuretic effect of ADH in
normal animals and pathological states of water retention
[10—15]. However, there are still some problems. For example,
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the ADH analogues are V1V2 antagonists, but not pure V2
antagonists. Chronically administered ADH analogues lose the
antagonism to the antidiuretic effect of ADH and show the
agonistic effect of ADH [16, 17]. The ADH analogues are
limited to parenteral use. Also, there is a species difference in
the antagonistic effect of ADH analogues on the antidiuretic
action of ADH [18]. Yamamura et al [19] have recently devel-
oped a newly synthesized, orally effective non-peptide ADH
antagonist, 5-dimethylamino-1{4-(2-methylbenzoylamino)ben-
zoyl}-2,3,4,5-tetrahydro- lH-benzazepine (OPC-3 1260). OPC-
31260 blocks the binding of ADH to plasma membranes of
kidney in a competitive manner.
In the present study we determined whether chronic admin-
istration of non-peptide ADH antagonist could treat the patho-
genesis of hyponatremia in SIADH rats which were continu-
ously receiving l-deamino-8-D-arginine vasopressin (dDAVP).
Methods
Animal models
The experimental procedure was modified from the method
of Verbalis and Drutarosky [20, 21]. Male Sprague-Dawley rats
weighing 200 to 250 g were used. They were housed individually
in cages at room temperature of 21 to 23°C with light on from
8 a.m. to 8 p.m. They were acclimated for four days to a
commercial, nutritionally-balanced liquid diet (Japan Clea Co.,
Tokyo, Japan). The formula of this liquid diet supplies 1.0
kcallml consisting of 56% carbohydrate, 16% protein and 17%
fat along with 48 mEq/day sodium, 12.1 glday glucose, vitamins
and trace elements. The liquid diet was supplied to the animals
at approximately 60 mI/day in 100-mi glass liquid feeding tubes
(Liquid Diet Feeding Tube, Bio-Serv, Frenchtown, New Jer-
sey, USA). After implanting an osmotic minipump (Alza model
2002, Palo Alto, California, USA), the liquid diet Was changed
to that containing 14% dextrose, which caloric density was 1.9
kcallml, supply 40 mi/day in 100-mi glass liquid feeding tubes.
Osmotic minipumps containing dDAVP (Kyowa-Hakko Co.,
Tokyo, Japan) dissolved in 0.15 M NaC1 at a concentration of 10
jig/mi were implanted subcutaneously along the back under
ether anesthesia. dDAVP was infused at a rate of 5 ng/hr. The
control group of animals were infused 0.15 M NaC1 at a similar
rate. After the recovery, the animals were placed in cages with
access to the modified liquid diet, but without water bottles for
an additional 14 days.
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OPC3 12605 mg/kg P.O.
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OPC3 1260 5 mg/kg P.O.
OPC31 2605mg/kg P.O. Vehicle P.O.
Diet [STO liquid diet (1 .0 kcal/ml) 60 mI/day Liquid diet containing 14% dextrose(1 .9 kcal/mI) 40 mI/day J Fig. 1. Schema of the present experimental
protocol.
Experimental protocols
Two groups of animals were studied, as shown in Figure 1.
The control group had two subgroups of Group 1 and 2. Group
1 was the control rats (infusion of vehicle, 0.15 M NaC1 only)
that were given the vehicle (H20) for OPC-31260 orally once a
day in a volume of 3.0 mllkg on days 7 to 13. Group 2 was
comprised of the control rats (infusion of vehicle, 0.15 M NaC1
only), that were given 5 mg/kg OPC-31260 orally once a day in
a volume of 3.0 ml/kg on days 7 to 13. Experimental group had
three subgroups of Group 3, 4, and 5. In Group 3, the animals
were given dDAVP (5 nglhr) subcutaneously by osmotic mini-
pump, and were administered the vehicle for OPC-3 1260 orally
once a day in a volume of 3.0 mI/kg on days 7 to 13. Group 4 of
animals was administered dDAVP (5 ng/hr) subcutaneously by
osmotic minipump, and was given 5 mg/kg OPC-3 1260 orally
once a day in a volume of 3.0 mI/kg on days 7 to 13. In Group
5 the animals were given dDAVP (5 ng!hr) subcutaneously by
osmotic minipump, and were given 5 mg/kg OPC-31260 orally
once a day in volume of 3.0 mI/kg on days 7 to 9, followed by
the vehicle on days 10 to 13. One ml of blood samples were
collected from tail blood vessels two days prior to the implan-
tation of osmotic minipumps and on days 2, 4, 6, 8, 10, 12, and
14. Serum sodium, serum osmolality and hematocrit were
determined. Serum Na was measured by flame photometer
(Model 736, Hitachi, Tokyo, Japan) and Süsm by freezing-point
depression (Model 3W2, Advanced Instrument, Massachusetts,
USA). In addition, body weight was measured every day during
the observation period.
Metabolic study
Urine volume, urinary osmolality (Usm) and urinary excre-
tion of Na (UNa) were determined in the aforementioned four
groups of animals without the Group 5, and the experimental
protocol was similar to that described earlier. The four groups
of animals were prepared independent of the studies described
above. Animals were placed in individual metabolic cages
during the observation period. Twenty-four-hour urine collec-
tion was made two days prior to the implantation of osmotic
minipump, and on days 2, 6, 7, 8, 9 and 13. Usm was measured
by freezing-point depression.
Statistics
All values of body weight, 5Na' Sosm, hematOcrit, urine
volume, Uosm and UNa were analyzed by multiple variance
using Scheffe's method and Student's t-test. A P value less than
0.05 was considered significant.
Results
The effect of OPC-3 1260 on SNa levels in the experimental
SIADH rats is depicted in Figure 2. In groups of rats receiving
dDAVP, the levels of SNa decreased to below 125 mEq/liter on
day 2 and reached to the bottom levels of 117.1 1.0 mEq/liter
on days 4 to 6. Hyponatremia was persistent throughout the
observation period in Group 3 receiving dDAVP and the vehicle
for OPC-3 1260. In Group 4 receiving dDAVP and OPC-3 1260,
Group 3 (DDAVP/vehicle)
Group 4 (DDAVP/OPC31 260)
Group 5 (DDAVP/OPC3 1260 and vehicle)
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Fig. 2. Alteration in serum sodium levels in the experimental SJADH
rats in the presence and absence of OPC-31260. Symbols are: (O—O)
Group 1, vehicle/vehicle; (Ll----D) Group 2, vehicle/OPC-3 1260;(S I) Group 3, DDAVP/vehicle; ( U) Group 4, DDAVP/OPC-
31260; and (A----A) Group 5, DDAVP/OPC-31260 + vehicle. Values are
means SEM, N = 6.
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Fig. 3. Alteration in serum osmolality in the experimental SIADH rats
in the presence and absence of OPC-31260. Symbols are: (O—O)
Group 1, vehicle/vehicle; (D----) Group 2, vehicle/OPC-3 1260;
(• •) Group 3, DDAVP/vehicle; (U U) Group 4, DDAVP/OPC-
31260; and (A----A) Group 5, DDAVP/OPC-31260 + vehicle. Values are
means SCM, N = 6.
SNa level promptly elevated to 133.8 1.9 mEq/l half a day
after the oral administration of 5 mg/kg OPC-31260. Its levels
remained within the normal range during the rest of observation
period, and the value was not significantly different from that of
rats receiving 0.15 M NaCI, a vehicle for dDAVP. However,
when the administration of OPC-3 1260 was ceased on day 9 SNa
levels decreased to 123.7 1.2 mEq/liter again (Group 5). In
contrast, in the Groups 1 and 2 of rats receiving 0.15 M NaC1
SNa levels were within the nOrmal range in the presence and
absence of OPC-3 1260. Quite similar results were obtained with
the changes in Ssm in the experimental SIADH rats, as shown
in Figure 3.
Figure 4 shows changes in body weight during the observa-
tion period. All five groups of animals gained body weight. Two
groups of rats receiving dDAVP (Groups 4 and 5)significantly
lost body weight after the administration of OPC-3 1260, and
body weight recovered in four days to levels that were similar to
that before the OPC-3 1260 administration.
Hematocrit ranged from 41.1 to 51.4% at the start of exper-
iments. In all five groups of rats hematocrit gradually decreased
during the observation period. This alteration probably de-
pended on frequent blood collection (data not shown).
Urine volume and Usm are shown in Figures 5 and 6. There
were no significant differences in urinary volume and Uosm on
days 2 and 6 between Groups 1 and 2 and between Groups 3 and
4 receiving dDAVP or not, for the times before the administra-
tion of the ADH antagonist. In the Groups 3 and 4 receiving
dDAVP which were in the hyponatremic state, urinary volumes
were significantly less whereas Usm was significantly greater
than those of the Groups 1 and 2 receiving the 0.15 M NaCl
vehicle. The oral administration of 5 mg/kg OPC-3 1260 was
begun on day 7. The administration of OPC-3 1260 markedly
increased urinary volume to 26.7 2.1 from 10.4 1.5 mI/day,
Time, day
Fig. 4. Changes in body weight in the experimental SIADH rats in the
presence and absence of OPC-31260. Symbols are: (O—O) Group 1,
vehicle/vehicle; (D----L1) Group 2, vehicle/OPC-31260; (• •) Group
3, DDAVP/vehicle; (U U) Group 4, DDAVP/OPC-3l260; and
(A----A) Group 5, DDAVP/OPC-31260 + vehicle. Values are means
SEM, N = 6.
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Fig. 5. Changes in urinary volume in the experimental SIADH rats in
the presence and absence of OPC-31260. Symbols are: (U —U) Group
4; (• •) Group 3; (D----L) Group 2; and (O—O) Group 1. Values
are mean SEM, N = 4.
and decreased Uosm to 463 52 from 1661 179 mOsm/kg
H20 in the Group 4 receiving dDAVP. A similar alteration was
obtained on day 8, but on day 9 and later, urinary volume and
Uosm came back to the levels similar to those of other three
groups despite of continuing the administration of OPC-3 1260.
In the other three groups of rats (Groups 1, 2, and 3), there was
not any significant difference in urinary volume and U0,,,
between the presence and absence of OPC-3 1260. As not shown
in Figures 5 and 6, great differences in urinary volume and Usm
were obtained before and after the insertion of osmotic mini-
pump, because two kinds of liquid diet were used. Rats were
given 60 mI/day of liquid diet and 40 mI/day of the modified
liquid diet before and after the osmotic minipump, respectively
(data not shown).
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The urinary excretion of Na was also found in the experi-
mental SIADFI rats in the presence and absence of 5 mg/kg
OPC-3 1260. There was not any difference in UNa among four
groups of rats during the observation period.
Discussion
The animal model chosen in the present study was charac-
terized by subcutaneous administration of dDAVP using os-
motic minipump and oral intake of liquid diet. This model was
originally developed by Verbalis and Drutarosky [20, 21].
Serum Na levels decreased to below 120 mEq/liter on day 4,
and hyponatremia was kept throughout the rest of observation
period. This model should be called "experimental SIADH" in
rats. The maneuver produced experimental SIADH with suc-
cess of more than 90%.
OPC-31260 has been developed by Yamamura et al, which is
effective to antagonize to the antidiuretic action of ADH [19].
OPC-3 1260 blocked the binding of 3H-ADH to the plasma
membrane preparations from rat kidney in a competitive man-
ner. We found that in cultured rat renal papillary collecting
tubule cells OPC-3 1260 reduced the ADH-induced cellu-
lar cAMP production in a dose-dependent manner [221. Its
maximal inhibition was 61% of cellular cAMP production
stimulated by ADH, which was weaker than the effect of
d(CH2)5DTyr(Et)VAVP, because d(CH2)5DTyr(Et)VAVP com-
pletely blocked the ADH-stimulated cAMP production. In
conscious rats the oral administration of 5 mg/kg OPC-3 1260
reduced U0sm to below 353 31 mOsm/kg H20 and increased
urine volume under ad libitum water drinking, and this effect
lasted at least 12 hours [23]. In addition the subcutaneous
administration of 1 ng/hr dDAVP increased U0sm to 1762 166
mOsm/kg H20 from 231 23 mOsm/kg H20 and reduced urine
volume to 12.6 1.2 mi/day from 148.7 18.8 mllday in
homozygous Brattleboro rats. Such changes were totally abol-
ished when 30 mg/kg OPC-3 1260 was administered orally [23].
These studies indicate that OPC-3 1260 antagonizes to the
antidiuretic action of endogenous and exogenous ADH, sug-
gesting that OPC-3 1260 is a selective, orally effective non-
peptide V2 ADH antagonist.
In the present study we examined whether chronic adminis-
tration of OPC-3 1260 normalizes SNa levels and S0 in the
experimental SIADH rats. We chose the dose of 5 mg/kg
OPC-3 1260, which significantly caused an increase in urine in
normally hydrated rats. Hyponatremia persisted during the
period when dDAVP was continuously administered by os-
motic minipump. The administration of 5 mg/kg OPC-3 1260
promptly increased SNa level to 133.8 1.9 mEq/liter from
118.5 1.9 mEq/liter in half a day, followed by a normalization
of 5Na levels to higher than 136 mEq/iiter during the rest of the
observation period. In contrast, the cease of administration of
OPC-3 1260 again decreased the SNa levels in rats receiving
dDAVP. Such an alteration was not found in rats receiving
water for the vehicle of OPC-3 1260. A change in 5Na levels may
be associated with that in circulatory blood volume in two
groups of rats receiving dDAVP and OPC-31260, because of
transient loss of body weight on day 8 when the administration
of OPC-3 1260 was started. The administration of OPC-3 1260
promptly caused marked water diuresis on day 7 in Group 4
hyponatremic rats receiving dDAVP. We observed a marked
increase in urine volume and a decrease in Usm in the
hyponatremic rats after the start of OPC-31260 administration.
These results of metabolic study indicate dilutional hyponatre-
mia in the hyponatremic rats receiving dDAVP and 40 mllday
liquid diet. Similar results were obtained in experimental
SIADH animals with ADH analogue, d(CH2)5Tyr(Et)VAVP or
d(CH2)5D.Tyr(Et)VAVP [8, 91. In those studies, SIADH was
made by subcutaneous injection of pitressin or dDAVP, and
ADH analogues were administered intravenously or intraperi-
toneally. We observed the antagonistic effect of OPC-3 1260 in
SIADH rats during the observation period of seven days, and
the effect of OPC-3 1260 persisted. There was not any tachy-
phylaxis of OPC-3 1260. Furthermore, we tried to use 30 mg/kg
OPC-3 1260 orally in experimental SIADH rats. Serum Na and
Osm levels promptly increased to 142.3 5.4 from 116.2 1.6
mEq/liter and 297.8 7.3 from 248.5 5,4 mOsm/H20,
respectively, in the hyponatremic rats receiving dDAVP (N =
6). These animals decreased their activity, including drinking
behavior, and died in two to four days after the administration
of 30 mg/kg OPC-3 1260. This might be due to a rapid correction
of SNa, though we have not examined the central pons histo-
logically [241.
In summary, the present study demonstrated the efficacy of a
newly synthesized, orally effective non-peptide ADH antago-
nist OPC-31260 in experimental SIADH produced by exoge-
nous dDAVP and the liquid diet. Clinical improvement of
abnormal states of water retention, as well as the provision of
important pathophysiological information regarding ADH de-
pendent and ADH independent factors in abnormal water
retention might be expected by the use of this ADH antagonist
in a wide variety of disorders of impaired water excretion.
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Fig. 6. Alterations in urinary osmolalily (U0,) in the experimental
SIADH rats in the presence and absence of OPC-31260. Symbols are:
(U U) Group 4;(• •) Group 3; (D----E1) Group 2; and (O—O)
Group 1. Values are means 5EM, N = 4.
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